Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.46 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | LTK | P29376 | 2/20 | 0.46 |
| ▸ | CDK8 | P49336 | 2/20 | 0.46 |
| ▸ | PRKX | P51817 | 2/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.46 |
| ▸ | STK3 | Q13188 | 2/20 | 0.46 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.46 |
| ▸ | BRSK1 | Q8TDC3 | 2/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18809334 | 0.92 | ROCK2 (0.42) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| Pyridine SCHEMBL27499200 | 0.84 | ROCK2 (0.54) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| SCHEMBL10270878 | 0.84 | ALOX5 (0.43) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| SCHEMBL8073959 | 0.84 | ALOX5 (0.43) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| SCHEMBL659048 | 0.84 | ALOX5 (0.43) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| SCHEMBL5147855 | 0.82 | ROCK2 (0.46) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| SCHEMBL6483753 | 0.82 | ALOX5 (0.42) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| SCHEMBL3501685 | 0.82 | ROCK2 (0.46) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| SCHEMBL9505616 | 0.82 | ROCK2 (0.46) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| SCHEMBL18560541 | 0.81 | SMN1; SMN2 (0.39) | ROCK2ROCK1PKN2RPS6KA5LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100438910-C | Preventives/remedies for liver diseases | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2008-12-03 | — | — | CN | claimed |
| CN-1362884-A | Preventives/remedies for liver diseases | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2002-08-07 | — | — | CN | claimed |
| CN-1358102-A | Preventives/remedies for angiostenosis | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2002-07-10 | — | — | CN | claimed |
| CN-1287494-A | Preventive/remedy for glaucoma | SENJI PHARMACEUTICAL CO LTD (JP) | 2001-03-14 | — | — | CN | claimed |
| US-20260049275-A1 | INDUCED STEM CELLS | UNIV MONASH (AU) | 2026-02-19 | — | — | US | disclosed |
| US-12492372-B2 | Induced stem cells | MONASH UNIVERSITY (AU) | 2025-12-09 | — | — | US | disclosed |
| US-12060581-B2 | Methods and cellular structures | MONASH UNIVERSITY (AU) | 2024-08-13 | — | — | US | disclosed |
| US-20240209323-A1 | METHODS AND CELLULAR STRUCTURES | MONASH UNIVERSITY (AU) | 2024-06-27 | — | — | US | disclosed |
| EP-4251739-A1 | INDUCED STEM CELLS | Monash University (AU) | 2023-10-04 | — | — | EP | disclosed |
| US-20220403343-A1 | METHODS OF REPROGRAMMING A CELL | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2022-12-22 | — | — | US | disclosed |
| US-20220389376-A1 | Methods for Reprogramming Cells | NANTES UNIVERSITE (FR) | 2022-12-08 | — | — | US | disclosed |
| EP-4058565-A1 | METHODS FOR REPROGRAMMING CELLS | Monash University (AU) | 2022-09-21 | — | — | EP | disclosed |
| CN-1293878-C | Preventing or curing agent for eye fatigue and pseudomyopia | SENJU PHARMA CO (JP) | 2007-01-10 | — | — | CN | disclosed |
| EP-1539247-A2 | ALPHA 5 BETA 1 AND ITS ABILITY TO REGULATE THE CELL SURVIVAL PATHWAY | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2005-06-15 | — | — | EP | disclosed |
| CN-1195547-C | Preventive/remedy for glaucoma | SENJI PHARMACEUTICAL CO LTD (JP) | 2005-04-06 | — | — | CN | disclosed |
| WO-2004043340-A2 | ALPHA 5 BETA 1 AND ITS ABILITY TO REGULATE THE CELL SURVIVAL PATHWAY | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2004-05-27 | — | — | WO | disclosed |
| CN-1494903-A | Preventing or curing agent for eye fatigue and pseudomyopia | ǧ����ҩ��ʽ���� | 2004-05-12 | — | — | CN | disclosed |
| CN-1362884-A | Preventives/remedies for liver diseases | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2002-08-07 | — | — | CN | disclosed |
| CN-1358102-A | Preventives/remedies for angiostenosis | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2002-07-10 | — | — | CN | disclosed |
| CN-1287494-A | Preventive/remedy for glaucoma | SENJI PHARMACEUTICAL CO LTD (JP) | 2001-03-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049275-A1 | INDUCED STEM CELLS | SALL4, SOX18, LEF1 | ROCK2 991/4885ROCK1 345/4885PKN2 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.